Stocks News

LAST PRICE
26.6300
TODAY'S CHANGE (%)
Trending Down-1.4200 (-5.0624%)

Bid / Lots
26.6100/ 50
Ask / Lots
27.0000/ 8
Open / Previous Close
28.0000 / 28.0500
Day Range
Low 26.4100
High 28.0300
52 Week Range
Low 24.6700
High 45.5800
Volume
1,566,949
above average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Nov 8, 2024
- DJ Immunovant Price Target Maintained With a $51.00/Share by HC Wainwright & Co., from 6:27AM ET on Friday Nov 08, 2024 by Dow Jones
  6:27AM ET on Friday Nov 08, 2024 by Dow Jones
  Companies Mentioned: IMVT
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/IMVT/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 08, 2024 06:27 ET (11:27 GMT)
Nov 7, 2024
- CORRECTION:-- Earnings Flash (IMVT) IMMUNOVANT Reports Q2 Loss $-0.74 Per Share, from 9:06AM ET on Thursday Nov 07, 2024 by MT Newswires
  9:06AM ET on Thursday Nov 07, 2024 by MT Newswires
  Companies Mentioned: IMVT
  09:06 AM EST, 11/07/2024 (MT Newswires) -- ...
- Immunovant Fiscal Q2 Net Loss Widens, from 8:56AM ET on Thursday Nov 07, 2024 by MT Newswires
  8:56AM ET on Thursday Nov 07, 2024 by MT Newswires
  Companies Mentioned: IMVT
  08:56 AM EST, 11/07/2024 (MT Newswires) -- Immunovant (IMVT) reported a fiscal Q2 net loss Thursday of $0.74 per diluted share, widening from a loss of $0.45 a year earlier. Analysts polled by Capital IQ expected a loss of $0.60. The clinical-stage ...
- -- Earnings Flash (IMVT) IMMUNOVANT Reports Q3 Loss $-0.74 Per Share, from 6:38AM ET on Thursday Nov 07, 2024 by MT Newswires
  6:38AM ET on Thursday Nov 07, 2024 by MT Newswires
  Companies Mentioned: IMVT
  06:38 AM EST, 11/07/2024 (MT Newswires) -- ...
- Press Release: Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024, from 6:30AM ET on Thursday Nov 07, 2024 by Dow Jones
  6:30AM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: IMVT

Today
- DJ BridgeBio Pharma Is Maintained at Sector Outperform by Scotiabank, from 5 hours ago by Dow Jones
  5 hours ago by Dow Jones
  Companies Mentioned: BBIO
Yesterday
- Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon, from 8:00AM ET on Thursday Nov 14, 2024 by PR Newswire
  8:00AM ET on Thursday Nov 14, 2024 by PR Newswire
  Companies Mentioned: IOVA, ONCY, SWTX, IBRX, SNDX
- Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon, from 8:00AM ET on Thursday Nov 14, 2024 by CNW Group
  8:00AM ET on Thursday Nov 14, 2024 by CNW Group
  Companies Mentioned: IOVA, ONCY, SWTX, IBRX, SNDX
- DJ MoonLake Immunotherap Price Target Maintained With a $100.00/Share by HC Wainwright & Co., from 7:00AM ET on Thursday Nov 14, 2024 by Dow Jones
  7:00AM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: MLTX
- DJ Biohaven Price Target Maintained With a $59.00/Share by HC Wainwright & Co., from 5:15AM ET on Thursday Nov 14, 2024 by Dow Jones
  5:15AM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: BHVN
Nov 13, 2024
- DJ Biohaven Is Maintained at Buy by TD Cowen, from 1:15PM ET on Wednesday Nov 13, 2024 by Dow Jones
  1:15PM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: BHVN
- DJ Biohaven Is Maintained at Outperform by RBC Capital, from 9:59AM ET on Wednesday Nov 13, 2024 by Dow Jones
  9:59AM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: BHVN
- MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody(R) sonelokimab in patients with active psoriatic arthritis, from 8:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
  8:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: MLTX
- RBC Cuts Price Target on Biohaven to $66 From $68, Keeps Outperform, Speculative Risk, from 7:50AM ET on Wednesday Nov 13, 2024 by MT Newswires
  7:50AM ET on Wednesday Nov 13, 2024 by MT Newswires
  Companies Mentioned: BHVN
Nov 12, 2024
- -- Earnings Flash (BHVN) BIOHAVEN Posts Q3 Loss $-1.74, from 4:23PM ET on Tuesday Nov 12, 2024 by MT Newswires
  4:23PM ET on Tuesday Nov 12, 2024 by MT Newswires
  Companies Mentioned: BHVN

Immunovant Inc
NASDAQ:IMVTUnited States

Search Criteria

Nov 8, 2024

DJ Immunovant Price Target Maintained With a $51.00/Share by HC Wainwright & Co., from 6:27AM ET on Friday Nov 08, 2024 by Dow Jones

Nov 7, 2024

CORRECTION:-- Earnings Flash (IMVT) IMMUNOVANT Reports Q2 Loss $-0.74 Per Share, from 9:06AM ET on Thursday Nov 07, 2024 by MT Newswires

Immunovant Fiscal Q2 Net Loss Widens, from 8:56AM ET on Thursday Nov 07, 2024 by MT Newswires

-- Earnings Flash (IMVT) IMMUNOVANT Reports Q3 Loss $-0.74 Per Share, from 6:38AM ET on Thursday Nov 07, 2024 by MT Newswires

Press Release: Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024, from 6:30AM ET on Thursday Nov 07, 2024 by Dow Jones

Peers Headlines

Today

DJ BridgeBio Pharma Is Maintained at Sector Outperform by Scotiabank, from 5 hours ago by Dow Jones

Yesterday

Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon, from 8:00AM ET on Thursday Nov 14, 2024 by PR Newswire

Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon, from 8:00AM ET on Thursday Nov 14, 2024 by CNW Group

DJ MoonLake Immunotherap Price Target Maintained With a $100.00/Share by HC Wainwright & Co., from 7:00AM ET on Thursday Nov 14, 2024 by Dow Jones

DJ Biohaven Price Target Maintained With a $59.00/Share by HC Wainwright & Co., from 5:15AM ET on Thursday Nov 14, 2024 by Dow Jones

Nov 13, 2024

DJ Biohaven Is Maintained at Buy by TD Cowen, from 1:15PM ET on Wednesday Nov 13, 2024 by Dow Jones

DJ Biohaven Is Maintained at Outperform by RBC Capital, from 9:59AM ET on Wednesday Nov 13, 2024 by Dow Jones

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody(R) sonelokimab in patients with active psoriatic arthritis, from 8:00AM ET on Wednesday Nov 13, 2024 by Dow Jones

RBC Cuts Price Target on Biohaven to $66 From $68, Keeps Outperform, Speculative Risk, from 7:50AM ET on Wednesday Nov 13, 2024 by MT Newswires

Nov 12, 2024

-- Earnings Flash (BHVN) BIOHAVEN Posts Q3 Loss $-1.74, from 4:23PM ET on Tuesday Nov 12, 2024 by MT Newswires